Vyne Therapeutics Inc

Vyne Therapeutics Inc (NASDAQ-GS: VYNE) is a specialty pharmaceutical Company. The Company is focused on the development and commercialization of proprietary therapies to address dermatology related issues.

Investment Highlights - Vyne Therapeutics Inc – Avoid at USD 6.37

• The Company generated good revenue in the financial year 2020, while remained in the development stage and has shown an increased loss.
• In the last six months, the Company delivered a negative return of ~17.49% and delivered lower returns compared to the benchmark Index.
• From the technical standpoint, shares were trading below the short-term support level of 20-day simple moving average prices of USD 7.03, which reflects a downtrend in the stock and can decline further.

Key Risks

• The covid-19 outbreak has resulted in disruptions in clinical trials which will have a negative impact on the Company’s performance.
• Any failure to meet the quality and comply with regulatory laws could lead to increased cost and even recall or suspension of products.

Financial Highlights – FY2020 (31 December 2020) (released on 4 March 2021)

(Source: Annual Report, Company Website)

• For the financial year 2020, driven by higher product sales, license revenues and royalty revenue, the revenue increased to $20,993 thousand.
• Due to higher operating expenses, the operating loss and the loss of the period increased in the financial year 2020.
• The cash balance as on 31 December 2020 increased to $57,563 thousand (31 December 2019: $43,759 thousand).

One Year Share Price Chart

(Source: Refinitiv, Thomson Reuters)

Conclusion

The Company has shown a decline in financial performance in the financial year 2020. The Company is in the development stage and hence rely on grants and cash balances to carry on all the business activities. The Company needs to manage operating expenses more effectively unless it will have negative impact on future financial and operational performance. VYNE generated revenue for the first time in 2020. The Bottom-line performance has declined, while profitability remained in the negative zone. Vyne Therapeutics operations are impacted by the outbreak of covid-19 pandemic and have been focusing on strengthening its balance sheet and reducing its costs to preserve cash. The stock made a 52-week low and high of USD 4.40 and USD 13.20, respectively.

Based on the above rationale, we have given an “Avoid” recommendation for Vyne Therapeutics Inc at the closing price of USD 6.37 (as on 8 April 2021), with support from few catalysts, needs to be evaluated at a later stage such as benefits of started commercial product sales.

Oragenics Inc

Oragenics Inc (AMEX: OGEN) is a US-listed healthcare Company. The Company is focused on creating TerraCoV2 immunization product to combat coronavirus pandemic and further development of effective treatments for infectious disease.

Investment Highlights - Oragenics Inc – Expensive at USD 0.8877

• The Company remained in the development stage and did not generate any revenue in FY2020, and profitability remained in the negative zone.
• As per valuation metrics, the Price/Earnings multiple of the Oragenics Inc is currently higher as compared to the corresponding multiple of the Pharmaceuticals & Medical Research industry, reflecting overstretched valuations.
• In the last one month, the Company delivered a negative return of ~28.98% and delivered lower returns compared to the benchmark Index.
• From the technical standpoint, shares were trading below the short-term support level of 20-day simple moving average prices of USD 0.9389, which reflects a downtrend in the stock and can decline further.

Key Risks

• Failure in cybersecurity and a critical data breach could hamper the operation as well as the reputation of the company.
• The Company’s operations are impacted by risks related to market trends, political change and change in the regulatory authority.

Recent News

On 9 March 2021, Oragenics announced that it has signed material transfer agreement with Biodextris Inc. As per the agreement, the Company will use three intranasal mucosal adjuvants in Terra CoV-2 vaccine to enhance their immunogenicity.

Financial Highlights – FY2020 (31 December 2020) (released on 1 March 2021)

(Source: Annual Report, Company Website)

• For the financial year 2020, the Company did not generate and revenue and witnessed an increase in operating expenses.
• The Company reported an increase in net loss to $26,430,699 in FY2020, due to higher operating expenses incurred.
• The Company reported cash balance of $17,639,575 as on 31 December 2020

One Year Share Price Chart

(Source: Refinitiv, Thomson Reuters)

Conclusion

The Company has shown a decline in financial performance in the financial year 2020. The Company is in the development stage and hence rely on grants and cash balances to carry on all the business activities, while profitability remained in the negative zone. Oragenics needs to manage its operating expenses unless it results in further deterioration in financial performance in the coming years. Due to the impact of the covid-19 pandemic, the Company experienced significant disruptions to business, manufacturing supply chain, financial condition, preclinical research to date and clinical trials. The stock made a 52-week low and high of USD 0.36 and USD 2.09, respectively.

Based on the factors as highlighted above, we believe the stock of Oragenics Inc is “Expensive” at the closing price of USD 0.8877 (as on 8 April 2021), with support from few catalysts needs to be evaluated at a later stage such as effective management of operating expenses.

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine do not hold interests in any of the securities or other financial products covered on the Kalkine website.